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ODS: Baseline data was analyzed from the Study of New
Onset Rheumatoid Arthritis (S.O.N.O.R.A.SM), a 5-year
prospective, longitudinal, inception cohort study to docu-
ment long-term functional, clinical, and humanistic out-
comes and patterns of treatment in patients with new
onset rheumatoid arthritis. Baseline data collection con-
sisted of RADAR and SF-36 via telephone interviews by
trained interviewers. To assess the correlation, Pearson
product moment correlation coefficients were calculated.
RESULTS: One hundred thirty-one patients completed
the baseline survey. Mean age of the sample was 56
years; 78% were female; 82% were Caucasian. SF-36’s
PF, RP, and BP scales had means of 54 (SE  0.02), 31
(SE  0.03), and 47 (SE  0.02), respectively. Mean
scores for RADAR items were 7.2 (SE  0.22) for “ar-
thritis activity over the past 6 months (AA6M)”, 4.9
(SE  0.23) for “arthritis activity today (AAT)”, 4.2 (SE 
0.22) for “arthritis pain today (APT)”, and 2.6 (SE 
0.15) for “morning stiffness today (MST)”. SF-36’s PF
scale correlated with AA6M (r  0.39, p  0.001), AAT
(r  0.49, p  0.001), APT (r  0.51, p  0.001), and
MST (r  0.40, p  0.001). SF-36’s RP scale correlated
with AA6M (r  0.37, p  0.001), AAT (r  0.38, p 
0.001), APT (r  0.44, p  0.001), and MST (r  0.33,
p  0.001). SF-36’s BP scale correlated with AA6M (r 
0.50, p  0.001), AAT (r  0.48, p  0.001), APT (r 
0.59, p  0.001), and MST (r  0.42, p  0.001). CON-
CLUSION: The SF-36’s BP domain resulted in the high-
est correlation with RADAR items. The APT item of
RADAR had the highest correlation with all three do-
mains of SF-36. These results suggest that the level of
bodily pain is indicative of functioning and well-being of
patients.
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An important weakness of economic models in the field
of osteoporosis has been the dependence on assumptions
or expert judgments rather than empirical estimates for
the utility values of key health events associated with os-
teoporosis. OBJECTIVES: This paper seeks to identify
the best available utility estimates for health states associ-
ated with osteoporosis and make recommendations about
their use. METHODS: This review has been based on a
systematic search of the main literature databases. Stud-
ies meeting the inclusion criteria have been reviewed in
terms of the appropriateness of the valuation technique,
the validity of the descriptive system (where one was
used), the number and type of respondents and overall
study quality. RESULTS: Twenty-three estimates of health
state values (HSVs) were found across four conditions
from five studies. These empirical estimates were found
to differ significantly from the commonly used assump-
tions in published economic models of interventions or
osteoporosis, but with a wide variation between esti-
mates for the same state (0.32 to 0.80) for vertebral frac-
ture states). This variation can be partly explained by
differences in the valuation technique, health state de-
scriptions and the background and perspective of the re-
spondent, and leaves considerable scope for discretion
that could be abused. There are also problems in apply-
ing values obtained from these studies to the populations
being examined in economic models and a particular dif-
ficulty in predicting the HSV in those who avoid a frac-
ture as a result of an intervention. CONCLUSION: The
review recommends a set of HSVs as part of a reference
case for use in economic models. Due to the paucity of
good quality estimates in this area, further recommenda-
tions are made regarding the design of future studies to
collect HSVs relevant to economic models.
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INTRODUCTION: Most current asthma outcome mea-
sures are either not sensitive enough to detect changes
caused by interventions or not broad enough to cover all
health domains affected by the disease. OBJECTIVE: To
develop a comprehensive measure of health outcomes for
children with asthma that is in compliance with the rec-
ommendations of the U.S. Panel on Cost-Effectiveness in
Health and Medicine, and compare health outcomes esti-
mated with that measure to those estimated with the
symptom-free day, the most commonly used measure.
METHODS: 1) Develop a multi-attribute Pediatric
Asthma Health Outcome Measure, PAHOM, that as-
sesses the impact of asthma on children’s symptoms,
emotions, and physical activity; 2) Collect data on prefer-
ence weights (Ui) for asthma health states from 101
adults using the standard gamble technique; 3) Collect
data on the incidence of health states (Pi) from 72 chil-
dren with asthma using PAHOM calendar; and 4) Calcu-
late the expected utility by summing all of (Ui*Pi). The
expected utility can be used as a proxy of health outcome
if it is assumed that health outcomes of these children are
constant for the remaining life years. RESULTS: On a
scale ranging from zero to one, where perfect health had
a score of one, the average utility of pediatric asthma pa-
tients in the study was 0.900 when measured with the
PAHOM, compared to 0.955 when measured with a
symptom-free day. CONCLUSION: PAHOM, a more
comprehensive measure of health outcomes than symp-
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tom-free day measure, provides lower estimates of aver-
age utility of asthma pediatric asthma patients.
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OBJECTIVES: To gain utility values for asthmatic pa-
tients, self-administered direct TTO questions may seem
to be a simple option. This study examined reported
TTO values by disease severity groups, and the relation-
ship between other health status measures, and with age.
METHODS: 228 consecutive adult outpatients and inpa-
tients at four sites in Hungary participated in the study.
Doctors had to report GINA severity group and lung
function values. Patients had to fill in three QoL ques-
tionnaires and a direct TTO question that offered a
choice between 20 years in current health or shorter
length of life in perfect health. Statistical analysis applied
F-statistics. RESULTS: Mean TTO values were 0.99,
0.96, 0.82, 0.73 in the four severity groups, respectively.
These were higher than corresponding EQ-5Dindex re-
sults of 0.93, 0.76, 0.65, 0.52. Correlation coefficients
between TTO values and EQ-5Dindex, EQ-5Dvas, SF-
36(PCS), SF-36(MCS), SGRQ, and FEV1% were 0.40,
0.40, 0.34, 0.25, 0.36, and 0.36, respectively. Age ex-
plained 23% of differences in TTO values after control-
ling for asthma severity. Within severity groups 4 and 3,
patients over 50 reported TTO values lower by 0.21 and
0.20 than those below this age. These differences were
larger than corresponding differences in EQ-5D index
values suggesting that direct TTO responses may incor-
porate different concepts of remaining life years of the
older. Results were statistically significant (p  0.0001).
CONCLUSIONS: Utility values gained from direct TTO
questions can lead to higher scores than generic utility-
based questionnaires, low correlation values with other
measures, and to biases in patient groups of heteroge-
neous age.
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OBJECTIVES: To develop a practical and scientifically
rigorous, patient-based outcome questionnaire to evalu-
ate symptoms in community-acquired pneumonia (CAP).
METHODS: The CAP-Symptom questionnaire (CAP-
Sym) is an 18-item, interviewer-administered question-
naire that measures the bothersomeness of 18 symptoms
during the past 24 hours using a 6-point Likert scale. We
used gold-standard psychometric methods to comprehen-
sively evaluate the acceptability, reliability, validity and
responsiveness of the CAP-Sym in field testing involving
556 patients in 13 countries. The development and vali-
dation of the CAP-Sym were carried out as part of the
CAP 2000 study, a multicentre, multinational, prospec-
tive, randomised, double-blind study to compare the ef-
fectiveness of moxifloxacin oral tablets to standard oral
treatment regimes in patients with CAP. RESULTS: Field
testing in all countries confirmed the acceptability (item
non-response, item endorsement frequencies, item/scale
floor and ceiling effects), reliability (internal consistency,
item-total and inter-item correlations, test-retest reliabil-
ity), validity (content, construct, convergent, discrimi-
nant, known groups) and responsiveness of the CAP-
Sym. CONCLUSIONS: The CAP-Sym is a practical and
scientifically sound patient-based outcome measure that
can be used to evaluate CAP-related symptoms in clinical
trials or clinical audit. The disease-specific CAP-Sym
shows preliminary evidence of being more responsive
than the generic SF-36 as a measure of outcome in CAP.
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OBJECTIVE: To forecast the discounted costs and clini-
cal consequences of inhaled corticosteroids (ICS) in a
population of adults with mild-to-moderate asthma.
METHODS: We developed a Markov, state-transition
simulation of asthma patient care and its pharmacoeco-
nomic impact. We employed this framework to compare
quick relievers (e.g., b-agonists) on an as-needed basis to
quick relievers plus ICS therapy targeted to one of three
severity sub-populations. State-space dimensions included
patient age, clinical history, and lung dysfunction (mea-
sured via forced expiratory volume in one second, FEV1).
Risk functions were estimated from symptom, exacerba-
tion, and hospitalization rates obtained from literature
reviews and analyses of primary, cross-sectional data. Sys-
tematic review of published trials yielded 16 eligible stud-
ies and produced the following outcome ranges for sensi-
tivity analysis: 1%–21% improvement in FEV1; monthly
costs of $14–$76; and 0%–4% probability of major tox-
icity. Societal costs were derived from published economic
studies of inpatient and outpatient asthma. We collected
preference weights (using standard gambles, time trade-
offs, and the Health Utilities Index) in a cross-sectional
